tirzepatide clinicaltrials.gov Highlighting 3 ongoing clinical trials of GLP-1 medications in breast and endometrial cancer. 1. FITWISE: for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/​HER2 Negative Breast Cancer 2. Tirzepatide Weight Loss Long-Term Safety of Tirzepatide: What

Quick Comparison Feature CagriSema Retatrutide Development owner Novo Nordisk Eli Lilly Core strategy Combination therapy Single-molecule multi-agonist Pathways Amylin + GLP-1 GIP + GLP-1 + glucagon Main components Cagrilintide + semaglutide Retatrutide (LY3437943) 2026 status Phase 3 / regulatory-watch candidate Phase 3 TRIUMPH program Best-fit research question Can amylin extend GLP-1 results

High-protein meals enhance tirzepatide effects because protein naturally stimulates GLP-1 and GIP release

110 Shinde, Deshmukh AD, More UK

In case of mild side effects or allergic reactions, visit your doctor

Your Voy clinical team can help you decide whether a maintenance dose, a planned break, or a restart makes the most sense for where you are